Berlin-based venture capital firm NaturalX Health Ventures has launched a €100M fund to drive the transformation of healthcare in Europe, focusing on consumer-centric health management.
The new fund is the first in Europe to focus on the intersection of consumer and healthcare, aiming to support the growth of innovative health solutions for European consumers.
NaturalX focuses on proactive health solutions such as sleep, gut health, prevention, and longevity, with an emphasis on mental health due to the rising demand for consumer-focused therapies.
How will the funds be utilised?
NaturalX Health Ventures’ new fund will primarily target Series-A investments, with the flexibility to participate in late Seed and Series-B rounds.
Investments will typically range from €3M – €5M, with up to €10M available per company. The fund will focus on consumer health startups in Europe, with selective investments in North America, and can act as a lead or co-investor.
Marvin Amberg, founder of NaturalX Health Ventures, says, “I am very excited to double down on our thesis with the official launch of naturalX. The consumer health space has been overlooked by investors.”
“We see an inflection point in Europe now, as consumers are finally taking more charge of their own health. Startups in the space need a partner with a shared vision.”
The fund is now fully operational and in the process of building its investment team across Europe.
Investing in health
NaturalX Health Ventures was founded by German serial entrepreneur Marvin Amberg in collaboration with Schwabe Group, a plant-based pharmaceutical manufacturing company.
The fund focuses on consumer health, which blends wellness and medicine through science-backed products and services centred on the consumer.
In its 18-month ramp-up phase, the VC firm has already invested in startups such as mybacs, Flow Neuroscience, Kyan Health, and Meela, while also backing healthcare-focused VC funds to strengthen its ecosystem.
Co-founder Amberg, says, “We analysed the US health market and in many successful startups, the consumer is already at the centre. Our thesis is that this is just the beginning, and the European market will develop in a similar pattern.”
“While we start to see some examples of consumer-focused healthcare companies in Europe reaching meaningful scale and significant funding, such as Oura or Neko Health, we think this market deserves more attention.”
Brief about Schwabe Group
The Schwabe Group is a collection of companies in the pharmaceutical and healthcare sectors, all focused on using plants as a foundation for health products and medicines.
The parent company, Dr. Willmar Schwabe GmbH & Co. KG, has been operating for over 150 years. With more than 4,000 employees, the group’s largest locations are in Germany, employing over 1,400 people.
International business now accounts for about 75 per cent of the group’s total turnover, which is around €950M. The group operates across all five continents, with a presence in Europe, South and Central America, Southeast Asia, the US, and China.
The Schwabe Group is led by Olaf Schwabe, the great-great-grandson of founder Dr. Willmar Schwabe, and the fifth generation of management.
01
10 years of Dutch Startup Visa dreams: A look back with Denis Chernobaev